Brokers Offer Predictions for Nuvation Bio FY2025 Earnings

by · The Cerbat Gem

Nuvation Bio Inc. (NYSE:NUVB – Free Report) – Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Nuvation Bio in a research report issued to clients and investors on Thursday, December 11th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.63) for the year, up from their previous forecast of ($0.64). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.34) EPS.

Several other research analysts also recently weighed in on NUVB. Jefferies Financial Group started coverage on shares of Nuvation Bio in a report on Tuesday, September 30th. They issued a “buy” rating and a $10.00 target price for the company. JMP Securities set a $10.00 price objective on Nuvation Bio in a research note on Thursday, November 20th. Citizens Jmp boosted their price target on Nuvation Bio from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, November 20th. Truist Financial set a $11.00 price objective on shares of Nuvation Bio in a report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.56.

Get Our Latest Stock Report on NUVB

Nuvation Bio Price Performance

Shares of NYSE:NUVB opened at $8.51 on Monday. The company has a market capitalization of $2.92 billion, a P/E ratio of -13.29 and a beta of 1.57. Nuvation Bio has a 1-year low of $1.54 and a 1-year high of $8.95. The firm’s 50 day simple moving average is $5.78 and its two-hundred day simple moving average is $3.73. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39.

Nuvation Bio (NYSE:NUVB – Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%.The company had revenue of $13.12 million during the quarter, compared to the consensus estimate of $7.48 million.

Insider Activity at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of the stock in a transaction on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Dongfang Liu sold 150,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at $140,760. This trade represents a 89.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 320,000 shares of company stock valued at $2,050,800 over the last ninety days. Corporate insiders own 29.93% of the company’s stock.

Institutional Trading of Nuvation Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss Life Asset Management Ltd bought a new position in shares of Nuvation Bio during the third quarter valued at approximately $39,000. CIBC Bancorp USA Inc. bought a new position in Nuvation Bio in the 3rd quarter valued at $98,000. Caitong International Asset Management Co. Ltd increased its stake in Nuvation Bio by 811.7% in the third quarter. Caitong International Asset Management Co. Ltd now owns 39,950 shares of the company’s stock worth $148,000 after purchasing an additional 35,568 shares during the period. Connective Capital Management LLC purchased a new stake in Nuvation Bio in the third quarter worth $369,000. Finally, Armistice Capital LLC lifted its position in shares of Nuvation Bio by 359.2% during the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock worth $8,495,000 after purchasing an additional 1,796,000 shares during the last quarter. 61.67% of the stock is owned by hedge funds and other institutional investors.

About Nuvation Bio

(Get Free Report)

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

Further Reading